Titan Pharmaceuticals Inc. (TTNP)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.81-0.13 (-2.19%)
As of 3:36 PM EDT. Market open.
People also watch:
VNDAIMUCBDSINAVBAEZS
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open5.91
Prev Close5.94
Bid5.81 x 100
Ask5.84 x 200
Day's Range5.80 - 6.03
52wk Range2.57 - 10.00
1y Target EstN/A
Market Cap123.17M
P/E Ratio (ttm)19.63
Beta1.38
Volume85,867
Avg Vol (3m)177,715
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Capital Cube6 days ago

    ETF’s with exposure to Titan Pharmaceuticals, Inc. : September 21, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Titan Pharmaceuticals, Inc. Here are 5 ETF’s with the largest exposure to TTNP-US. Comparing the performance and risk of Titan Pharmaceuticals, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Zacks Small Cap Researchlast month

    TTNP: Probuphine Licensing: EU & Australia In the Works

    During a recent call with Titan Pharmaceuticals (TTNP), we spoke with CEO Sunil Bhonsle and discussed the company’s current efforts to license Probuphine outside of the US and Canada.  As we have previously written, Titan and partner Braeburn Pharmaceuticals (Private) received FDA approval for the drug in late May.  Braeburn is responsible for the manufacture and marketing of the drug, and was able to rapidly fill the pipeline and train a substantial number of providers to perform the implantation procedure in the first several weeks following the nod from the FDA.  Within a month, Braeburn made the first sales of Probuphine and Titan began to receive royalties. Titan licensed to Braeburn the rights to sell Probuphine in the United States and Canada, retaining rights to sell the drug in the rest of the world.  Currently, Titan is seeking a meeting with the European Medicines Agency (EMA) to determine what data and efforts are required to gain approval.  The company is employing the services of a consultant and using its internal resources to identify the most efficient route to gain the agency’s assent and to find an appropriate partner to conduct training, marketing and sales.  Currently, Titan expects to meet with the EMA sometime in the fourth quarter.

  • Capital Cube2 months ago

    ETF’s with exposure to Titan Pharmaceuticals, Inc. : August 12, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Titan Pharmaceuticals, Inc. Here are 5 ETF’s with the largest exposure to TTNP-US. Comparing the performance and risk of Titan Pharmaceuticals, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)